Nora Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2007-01-01
- Employees
- 11
- Market Cap
- -
A Multi-center, Placebo-controlled Study to Evaluate NT100 in Pregnant Women With a History of Unexplained Recurrent Pregnancy Loss (RPL)
- First Posted Date
- 2014-06-05
- Last Posted Date
- 2015-07-15
- Lead Sponsor
- Nora Therapeutics, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT02156063
Follow-Up Of Pregnancies Established During Study NT-03 (Thrive-IVF Follow-Up)
Phase 2
Completed
- Conditions
- Repeated IVF Failure
- Interventions
- Other: Post dosing with PlaceboBiological: Post dosing with NT100
- First Posted Date
- 2013-11-07
- Last Posted Date
- 2015-09-14
- Lead Sponsor
- Nora Therapeutics, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT01978561
A Multi-Center Study To Evaluate Multiple Doses of NT100 Following IVF In Women With Repeated IVF Failures (Thrive-IVF)
- First Posted Date
- 2013-05-29
- Last Posted Date
- 2014-11-20
- Lead Sponsor
- Nora Therapeutics, Inc.
- Target Recruit Count
- 157
- Registration Number
- NCT01864356
- Locations
- 🇺🇸
Shady Grove Fertility, Rockville, Maryland, United States
🇺🇸HRC Fertility, Pasadena, California, United States
🇺🇸Florida Fertility Institute, Clearwater, Florida, United States
© Copyright 2025. All Rights Reserved by MedPath